Because deficiency of SMN mainly leads to the failure of mRNA process, our study provides a concept of potential therapy for NOA patients with abnormal splicing mRNA using the clinically applicable drug as used in SMA patients. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.